From Bench to Breakthrough: Decoding the Future of AI-Driven Medicine

A conversation with Amélie E. Bigorgne — Global AI Strategy Lead — on bridging the gap between disease complexity and machine intelligence.

By Louise Servoin · 2026-10-16 · 9 min read

## Amélie E. Bigorgne, PhD – Global AI Strategy & Translational Medicine

PhD in Immunology & Gastroenterology; expert in Translational Medicine; faculty at Inserm and Sick Children’s Hospital Necker, France. Former Roche Genentech Global Technology Innovation Lead, Product Development, Switzerland; former Associate Research Scientist at Seattle Children's and Seattle Biomedical Research Institute, WA, USA; former Translational Medicine Project Lead for Cancer Immunotherapy at Gustave Roussy Cancer Center, France. Trilingual in French, English, and German; based between Basel, Switzerland, and Paris, France.

Some experts specialize in the "what," others in the "how." Amélie E. Bigorgne operates in the "where"—specifically, the high-stakes territory where laboratory discoveries meet patient outcomes.

With a career forged in the prestigious innovation hub of Université Paris-Saclay, where she helped build a diagnostic platform for immuno-oncology, and at Université Paris Cité at Sick Children’s Necker Hospital, Amélie became the Global Lead for Technology Innovation and AI strategy implementation in clinical trials at Roche headquarters in the pharmaceutical heart of Basel, Switzerland.

Amélie has spent years decoding the immune system’s most stubborn mysteries. Now, from within a high-growth Stealth Startup, she is applying that same rigor to AI strategy. For Amélie, AI isn't just a tool for efficiency; it is the only language complex enough to speak back to medical predictive tools and accelerate clinical trials for the benefit of patients.

## Leading Translational Research: Bridging the Gap in Cancer Immunotherapy

You describe translational research as the “bench-to-bedside” bridge. In practice, how did you steer that process in cancer immunotherapy?

Translational research is the essential "bench-to-bedside" process that applies discoveries generated through basic scientific inquiry in the laboratory to the development of diagnostic tools, or human clinical trials to identify new treatments.

Over the last years, I led complex implementation projects in cancer immunotherapy, orchestrating cross-functional teams that bridge diverse domains. This involves working closely with surgeons to identify the patient samples to analyze, coordinating deep core technology and driving research, and collaborating with the Data Protection Officer (DPO) to navigate high-risk data processing and ensure strict GDPR compliance for patient privacy.

Furthermore, intellectual property strategy has to be implemented at the earliest stages of R&D, leading the patenting of core technologies to ensure our biological innovations are not only clinically effective but also commercially defensible and ownable in a crowded global landscape.

## The Molecular Roots of Strategy

Amélie, you have a deep academic and clinical background in Gastroenterology and Immunology from Paris University. How does a scientist trained in the granular details of clinical immunology complexity end up leading Global AI Strategy?

In immunology, you quickly realize that the "human machine" is the ultimate big data problem. A single immune response involves thousands of variables interacting in real time.

In the last two decades in research, I saw how often we reached the limits of traditional analysis models. I realized that to solve the next generation of medical challenges—like personalized immunotherapy—we needed a technology framework that could handle biological non-linearity.

I’m a scientist in essence; I’ve just traded the microscope for a different kind of lens—one that can see an applicable prediction power in millions of clinical data simultaneously. I also acquired a deep expertise in leading cross-functional initiatives—scientific experts, medical directors, business leads—which is key to apprehend complex concepts and create innovative solutions.

"I’m a scientist in essence; I’ve just traded the microscope for a different kind of lens—one that can see an applicable prediction power in millions of clinical data simultaneously." — Amélie E. Bigorgne

## The Stealth Shift: Speed vs. System

You recently transitioned into a “Stealth Startup” environment after years in more traditional life sciences ecosystems. What does the startup world allow you to do with AI that the established giants can’t?

It’s the difference between renovating an old mansion and building a smart home from scratch. In established institutions, AI is often "bolted on" to legacy systems and old data silos.

In our deeptech, we are building an AI-native engine. We can integrate data governance, machine learning, and translational strategy into the very foundation of the company. It allows for a level of technical and operational agility that is essential when you are trying to outpace the traditional 10-year drug discovery cycle.

## Basel, Europe's Boston: Where Tech Meets Bio

Basel is sometimes called the “New Boston in Europe.” Does being based there change how you approach innovation?

Absolutely. Basel provides a vibrant ecosystem. You have the heavyweights of pharma giants and the most agile biotech startups sharing the same networking events.

Basel is a peculiar environment of cutting-edge technology and business, combined with a mix of contemporary art and a deep grounding in cultural history. This proximity keeps your strategy grounded in reality and tradition. Basel forces a synthesis of numerous startups and companies, between "pure tech" and "pure bio," that you don't find anywhere else.

## AI in Medicine Must Be a Partner to Human Decision

In your field, the stakes are literally life and death. What is the biggest barrier to getting clinicians to trust AI-driven insights?

AI-based tools in medicine are increasingly accepted as a partner to human decision in a vast majority of clinicians. A doctor won't—and shouldn't—change a patient's treatment plan based on an approximate and subjective evaluation.

AI-driven medical decision support relies primarily on the deployment of software that enhances objectivity and increases precision. An added value which serves better the global clinical trials is the enabled global standardization.

The true barrier to trust is not merely the technology, but the lack of tools co-created with healthcare professionals to ensure seamless integration into clinical workflows. My mission in AI strategy is to leverage this unique understanding of disease complexity and a deep field knowledge in medical practice to identify unmet needs.

Without this domain expertise, it is impossible to build tailored tools that transform clinical challenges into precise and actionable solutions.

"AI in medicine must be a partner to human decision. A doctor shouldn't change a treatment plan based on a subjective and approximate evaluation." — Amélie E. Bigorgne

Tags: Innovation, AI Strategy, Translational Medicine, Immunology, Deeptech, HealthTech, Startup Leadership, Basel Life Sciences, Gustave Roussy, PSCC, Necker Hospital, Patient Clinical Trials, Inserm, Roche, Genentech